Abbott Laboratories (NYSE:ABT) issued its quarterly earnings data on Wednesday. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01, RTT News reports. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The business had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. During the same period in the prior year, the firm posted $0.59 EPS. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. Abbott Laboratories updated its Q4 guidance to $0.72-0.74 EPS.

Shares of Abbott Laboratories (NYSE ABT) opened at 55.06 on Wednesday. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $55.43. The stock has a market capitalization of $95.66 billion, a PE ratio of 77.11 and a beta of 1.06. The firm has a 50-day moving average of $52.59 and a 200 day moving average of $48.17.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be paid a $0.265 dividend. This represents a $1.06 annualized dividend and a yield of 1.93%. The ex-dividend date is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is presently 149.30%.

In other news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the business’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $52.95, for a total value of $3,307,257.00. Following the transaction, the insider now owns 113,426 shares of the company’s stock, valued at $6,005,906.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Stephen R. Fussell sold 196,550 shares of the business’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the transaction, the insider now directly owns 221,488 shares in the company, valued at approximately $10,963,656. The disclosure for this sale can be found here. Over the last quarter, insiders sold 333,310 shares of company stock valued at $16,857,255. Company insiders own 0.76% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Albion Financial Group UT purchased a new position in shares of Abbott Laboratories in the second quarter worth $211,000. Ackerman Capital Advisors LLC purchased a new position in shares of Abbott Laboratories in the second quarter worth $231,000. TLP Group LLC purchased a new position in shares of Abbott Laboratories in the second quarter worth $254,000. Coldstream Capital Management Inc. lifted its holdings in shares of Abbott Laboratories by 9.7% in the second quarter. Coldstream Capital Management Inc. now owns 5,484 shares of the healthcare product maker’s stock worth $267,000 after buying an additional 485 shares in the last quarter. Finally, Segment Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the second quarter worth $268,000. 71.45% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on ABT shares. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research report on Thursday, June 29th. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $54.00 price objective (up from $47.50) on shares of Abbott Laboratories in a research report on Friday, June 30th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $55.00 price objective (up from $48.00) on shares of Abbott Laboratories in a research report on Friday, July 14th. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $54.94.

TRADEMARK VIOLATION NOTICE: “Abbott Laboratories (ABT) Issues Earnings Results” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/18/abbott-laboratories-abt-issues-earnings-results.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Earnings History for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.